Dirk Biskup, Managing Director of CeGaT GmbH, shared a post on LinkedIn:
“Personalized oncology has made significant progress. However, molecular information is often used only once rather than guiding decisions continuously. This does not reflect how cancer behaves. Tumors evolve, resistance emerges, and treatment strategies must adapt over time.
To truly personalize cancer care, we need molecular insight following the patient journey, not genetic testing just at the moment of diagnosis. This requires a shift toward a longitudinal understanding of the disease.
At CeGaT, this thinking shapes how we design tumor diagnostics and how we treat patients here in Tübingen. Our portfolio is built to support clinical decisions from first diagnosis to long-term monitoring:
- precise genetic profiling at first diagnosis
- comprehensive tumor characterization for personalized therapy strategies
- evidence-based treatment recommendations
- liquid biopsy solutions (esp. MRD testing) for monitoring and relapse detection.”
Discover CeGaT’s tumor diagnostic portfolio
Other articles on Oncodaily.